Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
US Department of Justice
Johnson and Johnson
Federal Trade Commission
Medtronic
Mallinckrodt
Harvard Business School
McKinsey
QuintilesIMS
Cipla

Generated: October 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,241,946

« Back to Dashboard

Which drugs does patent 9,241,946 protect, and when does it expire?


Patent 9,241,946 protects ORACEA and is included in one NDA. There has been one Paragraph IV challenge on Oracea.

This patent has seventeen patent family members in twelve countries.

Summary for Patent: 9,241,946

Title:Methods of treating acne
Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.
Inventor(s): Ashley; Robert A. (Newtown, PA)
Assignee: GALDERMA LABORATORIES INC. (Fort Worth, TX)
Application Number:14/753,544
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Galderma Labs Lp
ORACEA
doxycycline
CAPSULE;ORAL050805-001May 26, 2006RXYesYes► Subscribe► Subscribe TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,241,946

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,603,506Methods of treating acne► Subscribe
7,014,858Use methods of treating acne and telangiectasia► Subscribe
7,232,572Methods of treating rosacea► Subscribe
8,052,983Methods of treating acne► Subscribe
8,658,189Methods of treating acne► Subscribe
7,211,267Methods of treating acne► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,241,946

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria330615► Subscribe
Australia2002303250► Subscribe
Canada2440472► Subscribe
Canada2719162► Subscribe
Germany60212613► Subscribe
Denmark1383508► Subscribe
European Patent Office1383508► Subscribe
European Patent Office1712236► Subscribe
European Patent Office1716856► Subscribe
European Patent Office2221056► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Queensland Health
Merck
QuintilesIMS
Novartis
Cipla
US Department of Justice
Boehringer Ingelheim
Accenture
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot